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We believe that patients with se-
vere combined immunodeﬁ  ciency 
and any form of mild local changes 
at the BCG injection site should be 
given single or double anti-TB ther-
apy, which should be continued until 
complete immunologic reconstitution 
occurs after bone marrow transplant. 
Severe local BCG infection with re-
gional lymph node involvement needs 
at least triple anti-TB therapy followed 
by long-term prophylaxis. Dissemi-
nated BCG infection needs anti-TB 
therapy, including >4 anti-TB drugs, 
until the patient fully recovers.
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Clindamycin-
resistant 
Streptococcus 
pneumoniae 
To the Editor: Antimicrobial 
medications classiﬁ   ed as macrolides 
(e.g., erythromycin) and lincosamides 
(e.g., clindamycin) show strong ac-
tivity against streptococci and are 
commonly used to treat community-
acquired infections caused by Strepto-
coccus pneumoniae. Moreover, these 
drugs are the recommended alterna-
tives for patients who cannot tolerate 
β-lactams.
Two main macrolide-resistant S. 
pneumoniae phenotypes have been re-
ported (1). The ﬁ  rst has a high level 
of resistance to all macrolides, lincos-
amides, ketolides, and streptogramins 
B due to ribosomal dimethylation, 23S 
rRNA mutations, or ribosomal protein 
mutations (MLSB, MSB, ML, MKSB, 
and K phenotypes). The second is 
characterized by a low-level resistance 
(e.g., MIC 2–4 mg/L) to only 14- and 
15-member ring macrolides (M phe-
notype) because of mef gene–medi-
ated active drug efﬂ  ux mechanism.
In January 2005, an erythromy-
cin-susceptible but clindamycin-resis-
tant pneumococcal strain was obtained 
from a conjunctival swab of a 10-
month-old female outpatient attending 
the daycare center of the Clinic and 
Laboratory of Infectious Diseases, 
Siena University, Siena, Italy. To our 
knowledge, such a phenotype has not 
been reported in the international lit-
erature for S. pneumoniae, although a 
similar phenotype of S. agalactiae was 
described by Malbruny et al. (2).
The  S. pneumoniae isolate was 
identiﬁ  ed by standard procedures (3) 
and conﬁ  rmed by PCR for the com-
mon capsule gene cpsA (4). Serotyp-
ing, performed by Quellung reaction, 
showed a 35F serotype. Susceptibility 
testing was carried out by disk dif-
fusion and conﬁ  rmed with E-test ac-
cording to Clinical and Laboratory LETTERS
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Standards Institute standards (5,6) for 
penicillin, ceftriaxone, ciproﬂ  oxacin, 
erythromycin, clindamycin, linezolid, 
and quinupristin-dalfopristin. For 
telithromycin, because an E-test strip 
was unavailable, a microbroth dilution 
method was used. 
The strain was susceptible to cef-
triaxone (MIC 0.125 mg/L), ciproﬂ  ox-
acin (MIC 0.125 mg/L), erythromycin 
(MIC 0.125 mg/L), linezolid (MIC 1.5 
mg/L), quinupristin/dalfopristin (MIC 
0.5 mg/L), and telithromycin (MIC 
<0.0035 mg/L); it was not susceptible 
to penicillin (MIC 0.125 mg/L) and 
was resistant to clindamycin (MIC 
1 mg/L). A triple disk–diffusion test 
with erythromycin, clindamycin, and 
josamycin was performed to test resis-
tance inducibility. No inducible pat-
tern was shown.
To understand the possible resis-
tance mechanism, MICs for 2 lincos-
amides (clindamycin and lincomycin) 
were determined by using a micro-
broth dilution method in the presence 
and absence of 10 mg/L of the ef-
ﬂ  ux pump inhibitor reserpine (Sigma 
Chemicals, St Louis, MO, USA), as 
described (7);  S.  pneumoniae ATCC 
49619 and S.  mitis 21A29 (mefE+) 
were used as controls (8). The MICs 
remained unchanged in the presence 
of reserpine: 1 mg/L for clindamycin 
and 4 mg/L for lincomycin.
The strain was screened for er-
mTR, ermB or mefA, and mefE deter-
minants as described (8,9). All PCR 
controls gave the expected results. 
No PCR product was obtained for the 
studied isolate.
Preliminary data did not show 
classic macrolide resistance determi-
nants for S. pneumoniae. Low-level 
lincosamide resistance suggests the 
presence of some efﬂ  ux mechanism, 
even if no inhibition by reserpine was 
observed. Moreover, no mutations of 
ribosomal proteins and of known bind-
ing sites for lincosamides in rRNA (1) 
were shown by sequencing of L22, 
L4, and 23S rRNA domain II and V 
genes with primers described by Canu 
et al. (10). Although these ﬁ  ndings are 
preliminary and the molecular basis 
for resistance is the subject of ongoing 
investigation, the identiﬁ  cation of this 
S. pneumoniae phenotype may affect 
clinical management of pneumococcal 
infections, especially in the treatment 
of patients intolerant of β-lactams.
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